The abstract is read at the publisher; the summary is JClub's.
rAAV-SA uses an NF-{kappa}B-responsive decoy minimal promoter to drive tumor-preferential surface expression of a synthetic antigen, enabling antigen-dependent CAR-T activation in TNBC and colorectal cancer xenografts.
- Why it matters: Solid tumors limit CAR-T therapy due to few suitable targets and an immunosuppressive microenvironment, creating a need for a shared, tumor-programmed antigen strategy.
- What they did: The study engineered tumor-responsive rAAV-SA and delivered it systemically with CAR-T cells, then built rAAV-ARMS to add tumor-local IL-15/IL-15R sushi-domain fusion, CXCL10, and IFN-{gamma}.
- The result: rAAV-SA plus CAR-T produced antitumor activity in TNBC and colorectal cancer xenograft models, and rAAV-ARMS enhanced CAR-T killing in 3D spheroids and increased intratumoral T-cell accumulation in TNBC, improving efficacy without overt systemic toxicity under tested conditions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.